Clinical trials: Non Insulin Dependent Diabetes
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare India (NCT01351922)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
ECC5004 RBA FE Study in Healthy Participants
This study is a Phase 1, open-label, randomized, single dose, fixed sequence, crossover study designed to compare the relative bioavailability of 50 mg ECC5004 current tablet formulation (F1) and 50 mg ECC5004 new tablet…
- Trial name
- NCT06268145
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Eccogene
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01263483
- Testing
- Alogliptin and voglibose, Voglibose
- Volunteers
- 230 people
- Sponsor
- Takeda
Type 2 Diabetes
GALLANT 4 Tesaglitazar vs. Glibenclamide
This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (glibenclamide) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone…
- Trial name
- NCT00255541
- Testing
- Tesaglitazar, Glibenclamide
- Where
- 66 sites in Belgium, Hong Kong and 11 more
- Volunteers
- 580 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Diabetes Mellitus, Type 2
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in…
- Trial name
- NCT00325429
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Primary Objective: To demonstrate the superiority of Soliqua 100/33 versus Lantus in the hemoglobin A1c (HbA1c) change within the overall population.
- Trial name
- LixiLan-D (NCT03434119)
- Testing
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Where
- 85 sites in United States
- Volunteers
- 241 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)
A single dose study to assess the safety, tolerability, pharmacokinetics and pharmacokinetics of MK6349 in Type 2 Diabetics.
- Trial name
- NCT00943371
- Testing
- MK6349
- Volunteers
- 28 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
This trial is conducted in Africa and Middle East. The objective of the study is to compare glycemic control of Biphasic insulin Aspart 30 twice daily with Biphasic insulin Aspart 30 twice daily plus Insulin Aspart, both insulin…
- Trial name
- NCT00282451
- Testing
- biphasic insulin aspart, insulin aspart
- Where
- 4 sites in Egypt, Saudi Arabia
- Volunteers
- 79 people
- Sponsor
- Novo Nordisk A/S
Diabetic Foot, Foot Ulcer
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
A multicenter, prospective, controlled clinical trial evaluating the efficacy of a single layer placental-based allograft and standard of care in the management of nonhealing diabetic foot ulcers.
- Conditions
- Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU
- Trial name
- NCT07159282
- Testing
- XWRAP
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Applied Biologics, LLC
Diabetes Mellitus, Type 2
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal…
- Trial name
- SeLan (NCT01234597)
- Testing
- INSULIN GLARGINE (HOE901), INSULIN GLULISINE (HMR1964)
- Where
- 11 sites in Israel
- Volunteers
- 219 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2 Diabetes Mellitus in Metformin monotherapy Who…
- Trial name
- NCT01970046
- Testing
- SP2086 50 mg b.i.d/Metformin, SP2086 50 mg q.d./Metformin
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus Type 2
Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas
To measure and compare the glycemic and insulinemic responses of subjects consuming a standard and two diabetes-specific products.
- Trial name
- NCT00540488
- Testing
- Adult enteral formula
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Abbott Nutrition
Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus
Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)
The purpose of this study is to demonstrate the efficacy and safety of the Fractyl duodenal mucosal resurfacing (DMR) Procedure using the Revita System compared to a sham procedure for the treatment of uncontrolled type 2…
- Trial name
- NCT02879383
- Testing
- DMR Procedure
- Where
- 11 sites in Belgium, Brazil and 3 more
- Volunteers
- 109 people
- Sponsor
- Fractyl Health Inc.
Diabetes, Diabetes Mellitus, Type 2
An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients
This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never…
- Trial name
- SAFE (NCT01077570)
- Testing
- repaglinide
- Where
- China
- Volunteers
- 2,033 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes, Dyslipidemia
Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)
A Multi-center, Randomized, double-blind, active-controlled, phase 3 trial to evaluate the safety and efficacy of Metformin/Atorvastatin in subjects with Type II Diabetes and dyslipidemia.
- Trial name
- NCT02947620
- Testing
- Metformin/Atorvastatin 1500mg/40mg, QD, Metformin 1500mg, QD, Atorvastatin 40mg, QD
- Where
- South Korea
- Volunteers
- 185 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension, Type 2 Diabetes
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit.
- Trial name
- NCT00803660
- Where
- 19 sites in Vietnam
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of aleglitazar in combination with metformin in patients with Type 2 diabetes mellitus who are inadequately…
- Trial name
- NCT01871415
- Testing
- aleglitazar, metformin
- Where
- 7 sites in China, South Korea
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche